Skip to main content
. 2015 Aug 3;126(19):2193–2201. doi: 10.1182/blood-2015-02-629600

Figure 2.

Figure 2

The percentages of PD-L1+ malignant and nonmalignant cells within the representative tumor area in 262 DLBCL samples. (A) The percentages of PD-L1+ malignant cells (blue bars) and PD-L1+ nonmalignant cells (green bars) among the total tissue cellularity. The red line indicates the percentage of PD-L1+ malignant cells among all malignant cells. The cases were sorted according to the percentage of PD-L1+ malignant cells among the total tissue cellularity. We set the threshold for PD-L1 positivity as 30% or more of PD-L1+ malignant cells among the total tissue cellularity. (B) The percentages of PD-L1+ malignant cells (blue bars) and PD-L1+ nonmalignant cells (green bars) among the total tissue cellularity in PD-L1– DLBCL samples (n = 218). The cases were sorted according to the percentage of PD-L1+ nonmalignant cells among the total tissue cellularity. We defined mPD-L1+ DLBCL as samples containing 20% or more PD-L1+ nonmalignant cells among the total tissue cellularity in PD-L1– DLBCL.